Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 1
2004 2
2005 1
2007 1
2008 1
2014 1
2018 1
2020 1
2022 1
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma.
Rohaan MW, Borch TH, van den Berg JH, Met Ö, Kessels R, Geukes Foppen MH, Stoltenborg Granhøj J, Nuijen B, Nijenhuis C, Jedema I, van Zon M, Scheij S, Beijnen JH, Hansen M, Voermans C, Noringriis IM, Monberg TJ, Holmstroem RB, Wever LDV, van Dijk M, Grijpink-Ongering LG, Valkenet LHM, Torres Acosta A, Karger M, Borgers JSW, Ten Ham RMT, Retèl VP, van Harten WH, Lalezari F, van Tinteren H, van der Veldt AAM, Hospers GAP, Stevense-den Boer MAM, Suijkerbuijk KPM, Aarts MJB, Piersma D, van den Eertwegh AJM, de Groot JB, Vreugdenhil G, Kapiteijn E, Boers-Sonderen MJ, Fiets WE, van den Berkmortel FWPJ, Ellebaek E, Hölmich LR, van Akkooi ACJ, van Houdt WJ, Wouters MWJM, van Thienen JV, Blank CU, Meerveld-Eggink A, Klobuch S, Wilgenhof S, Schumacher TN, Donia M, Svane IM, Haanen JBAG. Rohaan MW, et al. Among authors: fiets we. N Engl J Med. 2022 Dec 8;387(23):2113-2125. doi: 10.1056/NEJMoa2210233. N Engl J Med. 2022. PMID: 36477031 Clinical Trial.
A prospective cohort study on active surveillance after neoadjuvant chemoradiotherapy for esophageal cancer: protocol of Surgery As Needed for Oesophageal cancer-2.
van der Zijden CJ, Lagarde SM, Hermus M, Kranenburg LW, van Lanschot JJB, Mostert B, Nuyttens JJME, Oudijk L, van der Sluis PC, Spaander MCW, Valkema MJ, Valkema R, Wijnhoven BPL; SANO-2 study group. van der Zijden CJ, et al. BMC Cancer. 2023 Apr 10;23(1):327. doi: 10.1186/s12885-023-10747-z. BMC Cancer. 2023. PMID: 37038138 Free PMC article.
Methotrexate plus or minus cetuximab as first-line treatment in a recurrent or metastatic (R/M) squamous cell carcinoma population of the head and neck (SCCHN), unfit for cisplatin combination treatment, a phase Ib-randomized phase II study Commence.
Ham JC, van Meerten E, Fiets WE, Beerepoot LV, Jeurissen FJF, Slingerland M, Jonker MA, Husson O, van der Graaf WTA, van Herpen CML. Ham JC, et al. Among authors: fiets we. Head Neck. 2020 May;42(5):828-838. doi: 10.1002/hed.26053. Epub 2020 Jan 6. Head Neck. 2020. PMID: 31903657 Free PMC article. Clinical Trial.
Neoadjuvant chemoradiotherapy plus surgery versus active surveillance for oesophageal cancer: a stepped-wedge cluster randomised trial.
Noordman BJ, Wijnhoven BPL, Lagarde SM, Boonstra JJ, Coene PPLO, Dekker JWT, Doukas M, van der Gaast A, Heisterkamp J, Kouwenhoven EA, Nieuwenhuijzen GAP, Pierie JEN, Rosman C, van Sandick JW, van der Sangen MJC, Sosef MN, Spaander MCW, Valkema R, van der Zaag ES, Steyerberg EW, van Lanschot JJB; SANO-study group. Noordman BJ, et al. BMC Cancer. 2018 Feb 6;18(1):142. doi: 10.1186/s12885-018-4034-1. BMC Cancer. 2018. PMID: 29409469 Free PMC article.
A comparison of carboplatin and paclitaxel with cisplatinum and 5-fluorouracil in definitive chemoradiation in esophageal cancer patients.
Honing J, Smit JK, Muijs CT, Burgerhof JGM, de Groot JW, Paardekooper G, Muller K, Woutersen D, Legdeur MJC, Fiets WE, Slot A, Beukema JC, Plukker JTM, Hospers GAP. Honing J, et al. Among authors: fiets we. Ann Oncol. 2014 Mar;25(3):638-643. doi: 10.1093/annonc/mdt589. Epub 2014 Feb 2. Ann Oncol. 2014. PMID: 24492674 Free PMC article.
Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients.
Look MP, van Putten WL, Duffy MJ, Harbeck N, Christensen IJ, Thomssen C, Kates R, Spyratos F, Fernö M, Eppenberger-Castori S, Sweep CG, Ulm K, Peyrat JP, Martin PM, Magdelenat H, Brünner N, Duggan C, Lisboa BW, Bendahl PO, Quillien V, Daver A, Ricolleau G, Meijer-van Gelder ME, Manders P, Fiets WE, Blankenstein MA, Broët P, Romain S, Daxenbichler G, Windbichler G, Cufer T, Borstnar S, Kueng W, Beex LV, Klijn JG, O'Higgins N, Eppenberger U, Jänicke F, Schmitt M, Foekens JA. Look MP, et al. Among authors: fiets we. J Natl Cancer Inst. 2002 Jan 16;94(2):116-28. doi: 10.1093/jnci/94.2.116. J Natl Cancer Inst. 2002. PMID: 11792750 Free article.
15 results